SLE患者皮质类固醇治疗前后IL－2，sIL－2R及IL－6水平的比较

检测了１２例活动期ＳＬＥ病人皮质类固醇治疗前后血清中可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）及培养上清中ＩＬ－２的水平，并检测了其中９例病人血清Ｉ－Ｌ６水平。治疗前ＩＬ－２水平为１０．９±６．０Ｕ／ｍｌ，明显低于正常对照组（３８．３±１８．８Ｕ／ｍｌ），ｓＩＬ－２Ｒ水平为７０８±３６７Ｕ／ｍｌ，明显高于正常对照组（２１１±１３７Ｕ／ｍｌ），ＩＬ－６水平为７５．９±４２．５Ｕ／ｍ１，明显高于正常对照组（２１．３±５．８Ｕ／ｍｌ）。皮质类固醇治疗１～６个月后，ＩＬ－２，ｓＩＬ－２Ｒ及ＩＬ－６水平分别为３２．５±２５．６Ｕ／ｍｌ，３５２±１２０Ｕ／ｍｌ及５８±１９．３Ｕ／ｍｌ，均随着临床症状的好转而趋于正常。我们认为ＩＬ－２，ｓＩＬ－２Ｒ的检测可作为监测ＳＬＥ病情活动性的指标。ＩＬ－６的检测在ＳＬＥ病人中亦有一定意义。     

皮肌炎并肾病变与脑梗塞1例

患者女，２７岁。以四肢肌无力，肌痛４年，浮肿２月，右肢体活动不灵２周主诉入院。４年前在外院诊断为皮肌炎，经治疗好转。此后强的松减量１０ｍｇ／ｄ维持，近２月来颜面、双下肢浮肿，２周来右肢体活动不灵。体检：Ｔ３６．３℃，ＢＰ１６／１０ｋＰａ，营养差，神志...     

三联疗法治疗结节性痒疹86例

我所自1995年6月起采用强的松、雷公藤多甙、氨苯砜三种药物联合治疗结节性痒疹86例，效果良好。     

大剂量皮质类固醇激素联合环磷酰胺治疗重症天疱疮30例

采用大剂量皮质类固醇与环磷酰胺同时并用治疗重症天疱疮３０例。结果表明采用泼尼松相当量为６０ｍｇ／ｄ时控制病情者１２例，８０－１００ｍｇ／ｄ者８例，１２０－１５０ｍｇ／ｄ者６例，１８０ｍｇ／ｄ得１例，超过１８０ｍｇ／ｄ者３例。副作用包括血压升高、消化道出血、感染及精神症状，经上副作用经对症处理及皮质类固醇的迅速减量距减轻或消失。２６例患者近期痊愈，４例近期基本痊愈。结果证实联合用药具有疗效高。皮质类     

环孢素A治疗天疱疮10例报告

１０例住院天疱疮患者接受环孢素Ａ口服治疗，开始剂量为５ｍｇ／ｋｇ／ｄ，如果２个后症状无改善，则加用强的松片３０ｍｇ／ｄ。症状控制后减量维持。结果有３例红斑型，２例建常型患者单独应用环孢素Ａ治疗，症状即可控制，其余患者在联合强的松或银屑灵０．７５ｍｇ／ｋｇ／ｄ口服后，症状亦得到改善。     

康体多注射液治疗异位性皮炎38例疗效观察

临床资料　随机选择门诊和住院异位性皮炎（ＡＤ）患者６８例,均符合康克非等的诊断标准［１］。在１周内未用任何药物治疗。其中治疗组３８例,男１６例,女２２例,平均年龄２４．１３±７．１岁,对照组３０例,男１３例,女１７例,平均年龄２２．１±６．８岁。治疗组肌注康体多注射液（西安长城制药厂生产,以甘草甜素为主药的中西复方制剂,每支含甘草酸铵４ｍｇ,甘氨酸４０ｍｇ,Ｌ半胱氨酸３ｍｇ）４ｍｌ／ｄ;对照组口服息斯敏１０ｍｇ／ｄ,两组同时辅以Ｂ族维生素及维生素Ｃ,外涂不含激素的安抚止痒剂。用药前及治疗６周后…     

泛发性脓疱型银屑病并发血小板增高和急性胰腺炎1例

泛发性脓疱型银屑病可合并脏器受累，但同时出现血小板增高和急性胰腺炎尚未见报告。患者女，２７岁，患寻常型银屑病２０余年，经用皮质类固醇激素治疗，停药后周身出现脓疱，并反复发作３年。曾于１９９７年在我科住院治疗，当时查血小板６９２×１０９／Ｌ，予阿维Ａ酯（ｔｉｇａｓｏｎ）５０ｍｇ／ｄ口服，病情痊愈而出院。出院后复查血小板计数降至正常。２个月前因上感、咳嗽，病情再次加重，于１９９８年１月１２日拟诊“脓疱型银屑病”收住院。入院时体检：ｔ３８．２℃，Ｐ１２０次／ｍｉｎ，Ｒ２４次／ｍｉｎ，血压１３／９ｋＰａ…     

山莨菪碱与雷公藤多甙合用治疗过敏性紫癜42例临床观察

临床资料　男２４例，女１８例，年龄４～１４岁，病程２～２０天，其中单纯型２０例，胃肠型１３例，关节型７例，肾型２例。治疗方法　山莨菪碱０．５～１ｍｇ／ｋｇ．ｄ，雷公藤多甙片１ｍｇ／ｋｇ．ｄ，均分３次口服，有感染者或血常规中白细胞及中性粒细胞增高者加用抗生素治疗。７天为１个疗程，一般治疗２个疗程。治疗结果　治愈（皮疹消退，症状消失，大便潜血阴性，尿常规正常）４０例（９５％），好转（皮疹部分消退，症状部分消失）２例（５％）。１个疗程治愈２２例（５５％），２个疗程治愈１８例（４５％）。皮疹消退时间６天…     

9例Behcet‘s综合征治疗分析

９例Ｂｅｈｃｅｔ’ｓ综合征治疗分析王岸柳，陈长斌，张成志（北京天坛医院皮肤科１０００５０）从１９８７年至１９９３年，我科根据已报道的部分Ｂｅｈｅｅｔ’ｓ综合征的治疗方法，应用皮质类固醇激素、雷公藤、秋水仙碱、氨苯砜、左旋咪唑等药物（联合及分别应用）治...     

综合治疗痤疮155例疗效观察

临床资料男１０１例，女５４例。年龄１５～２９岁，病程１～１１年。治疗方法按不同类型皮疹分组，分别采用不同的治疗方法。Ａ组：丘疹型６２例，口服维生素Ｂ６６０ｍｇ／ｄ，葡萄糖酸锌４２０ｍｇ／ｄ，外搽复方硫磺洗剂Ⅰ号（硫磺６．０ｇ，樟脑０．５ｇ，阿拉伯胶１...     

New fillers for the new man

ABSTRACT:  Two new collagen-based lidocaine-containing dermal fillers, ArteSense™/ArteFill™ (Artes Medical, San Diego, CA) and Evolence® (Colbar LifeScience Ltd., Herzliya, Israel), have proved to be of particular interest to men, many of whom seek a long-lasting or permanent correction. ArteFill™ has been available in the United States since 2006, and it is expected that Evolence® will reach the American market in 2008. The properties of the two products will be described, and experience based on the administration of many hundreds of syringes of both products by a Canadian dermatologist will be detailed here, with tips and precautions to optimize patient outcomes.     

Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients

It is generally believed that ablative laser therapies result in prolonged healing and greater adverse events when compared with nonablative lasers for skin resurfacing. To evaluate the efficacy of ablative laser use for skin resurfacing and adverse events as a consequence of treatment in comparison to other modalities, a PRISMA‐compliant systematic review (Systematic Review Registration Number: 204016) of twelve electronic databases was conducted for the terms “ablative laser” and “skin resurfacing” from March 2002 until July 2020. Studies included meta‐analyses, randomized control trials, cohort studies, and case reports to facilitate evaluation of the data. All articles were evaluated for bias. The search strategy produced 34 studies. Of 1093 patients included in the studies of interest, adverse events were reported in a total of 106 patients (9.7%). Higher rates of adverse events were described in nonablative therapies (12.2% ± 2.19%, 31 events) when compared with ablative therapy (8.28% ± 2.46%, 81 events). 147 patients (13.4%) reported no side effects, 68 (6.22%) reported expected, transient self‐resolving events, and five (0.046%) presented with hypertrophic scarring. Excluding transient events, ablative lasers had fewer complications overall when compared with nonablative lasers (2.56% ± 2.19% vs 7.48% ± 3.29%). This systematic review suggests ablative laser use for skin resurfacing is a safe and effective modality to treat a range of pathologies from photodamage and acne scars to hidradenitis suppurativa and posttraumatic scarring from basal cell carcinoma excision. Further studies are needed, but these results suggest that ablative lasers are a superior, safe, and effective modality to treat damaged skin.     

Genetic alterations in RAS‐regulated pathway in acral lentiginous melanoma

Studies integrating clinicopathological and genetic features have revealed distinct patterns of genomic aberrations in Melanoma. Distributions of BRAF or NRAS mutations and gains of several oncogenes differ among melanoma subgroups, while 9p21 deletions are found in all melanoma subtypes. In the study, status of genes involved in cell cycle progression and apoptosis was evaluated in a panel of 17 frozen primary acral melanomas. NRAS mutations were found in 17% of the tumors. In contrast, BRAF mutations were not found. Gains of AURKA gene (20q13.3) were detected in 37.5% of samples, gains of CCND1 gene (11q13) or TERT gene (5p15.33) in 31.2% and gains of NRAS gene (1p13.2) in 25%. Alterations in 9p21 were identified in 69% of tumors. Gains of 11q13 and 20q13 were mutually exclusive, and 1p13.2 gain was associated with 5p15.33. Our findings showed that alterations in RAS‐related pathways are present in 87.5% of acral lentiginous melanomas.     

Self‐resolving superficial primary cutaneous mucormycosis in a 7‐week‐old infant

A 7‐week‐old girl, born at 30 weeks' gestational age, presented to clinic for evaluation of a crop of vesicular lesions that were noted after removal of a bandage that had been in place for 4 days. A punch biopsy of the lesion revealed fungal elements that were later identified as Rhizopus spp. The lesion began to self‐resolve, and no further treatment was needed, with full resolution of the lesion by 1 month after presentation. Clinicians should be aware of the variable presentations of mucormycosis and consider fungal infection in the differential diagnosis when evaluating vulnerable patients with skin eruptions.     

Pathogenic role of IL-17 in psoriasis and psoriatic arthritis

Psoriasis is a chronic inflammatory skin disorder resulting from a complex network of cytokines and chemokines produced by various immune cell types and tissue cells. Emerging evidence suggests a central role of IL-17 and IL-23/T17 axis in the pathogenesis of psoriasis, giving a rationale for using IL-17-blocking agents as therapeutics.Three agents targeting IL-17 signaling are being studied in Phase III clinical trials: secukinumab and ixekizumab (IL-17 neutralizing agents), and brodalumab (IL-17 receptor antagonist). Preliminary results are highly promising for all anti-IL17 agents, creating fair expectations on this class of agents as the new effective therapeutic approach for the treatment of psoriasis.